| Literature DB >> 32410986 |
Ruimin Tian1,2, Xianfeng Liu1, Yanqin Luo1, Shengnan Jiang1, Hong Liu3, Fengming You3, Chuan Zheng3, Jiasi Wu4.
Abstract
Colitis-associated cancer (CAC) is known as inflammatory bowel disease (IBD)-developed colorectal cancer, the pathogenesis of which involves the occurrence of apoptosis. Western drugs clinically applied to CAC are often single-targeted and exert many adverse reactions after long-term administration, so it is urgent to develop new drugs for the treatment of CAC. Herbal medicines commonly have multiple components with multiple targets, and most of them are low-toxicity. Some herbal medicines have been reported to ameliorate CAC through inducing apoptosis, but there is still a lack of systematic review. In this work, we reviewed articles published in Sci Finder, Web of Science, PubMed, Google Scholar, CNKI, and other databases in recent years by setting the keywords as apoptosis in combination with colitis-associated cancer. We summarized the herbal medicine extracts or their compounds that can prevent CAC by modulating apoptosis and analyzed the mechanism of action. The results show the following. (1) Herbal medicines regulate both the mitochondrial apoptosis pathway and death receptor apoptosis pathway. (2) Herbal medicines modulate the above two apoptotic pathways by affecting signal transductions of IL-6/STAT3, MAPK/NF-κ B, Oxidative stress, Non-canonical TGF-β1, WNT/β-catenin, and Cell cycle, thereby ameliorating CAC. We conclude that following. (1) Studies on the role of herbal medicine in regulating apoptosis through the Ras/Raf/ERK, WNT/β-catenin, and Cell cycle pathways have not yet been carried out in sufficient depth. (2) The active constituents of reported anti-CAC herbal medicine mainly include polyphenols, terpenoids, and saccharide. Also, we identified other herbal medicines with the constituents mentioned above as their main components, aiming to provide a reference for the clinical use of herbal medicine in the treatment of CAC. (3) New dosage forms can be utilized to elevate the targeting and reduce the toxicity of herbal medicine.Entities:
Keywords: apoptosis; colitis-associated cancer; herbal medicine; inflammatory bowel disease; signaling pathways
Year: 2020 PMID: 32410986 PMCID: PMC7199713 DOI: 10.3389/fphar.2020.00438
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Figure 1Effects of herbal medicine on the intrinsic pathway of apoptosis.
Figure 2Effects of herbal medicine on the extrinsic pathway of apoptosis.
Figure 3Molecular structures of reported anti-CAC compounds from herbal medicine.
Figure 4Reported anti-CAC herbal medicines. (A) Artemisia princeps Pampanini cv, (B) American ginseng, (C) Cocoa, (D) Licorice, (E) Mushroom Ganoderma lucidum, (F) Ginger, (G) Camellia sinensis L.O. Kuntze, (H) Lentinula edodes.
Figure 5Anti-CAC formulas documented in ancient books. (A) The prescriptions of the Bureau of Taiping People’s Welfare Pharmacy describing Shenling Baizhu San. (B) ‘Shang Han Lun’ documenting Huangqin Decoction. (C) ‘Plain Questions - anthology on proper therapy for Qi disorder and pathogenesis to save life’ describing Shaoyao Decoction.
Herbal medicines based on the above active components.
| Monomers | Medicinal plants | Reference |
|---|---|---|
| Crocin |
| |
| Embelin |
| |
| Parthenolide |
| |
| Oleuropein |
| |
| Wogonoside |
| |
| Oroxylin A |
| |
| Baicalein |
| |
| Silibinin |
| |
| Nobiletin |
| |
| Curcumin |
| |
| Resveratrol |
| |
| Celastrol |
| |
| Pristimerin |
| |
| Triptolide |
|
Figure 6Other sources of reported monomers with anti-CAC properties.
Effects of the monomers, extracts, or formulas of herbal medicines on apoptosis-related pathway molecules.
| Herbal medicine | Cell | Dose | Treatment time | Animal | Dose | Treatment time | Pathway | Related targets | Reference |
|---|---|---|---|---|---|---|---|---|---|
| Baicalein | HCT-116 | 25, 50, 100 μM | 24 h | Male ICR mice (five weeks old) | 1, 5, 10 mg/kg/d | 14 w | NF-κB, | Pro-caspase-3/-8/-9, PARP, pIκBα, p50, p65, iNOS, MMP-2 ↓ |
|
| Wogonoside | HCT116, HT29, THP-1 cells | 50, 100, 150 μM | 24 h | C57BL/6 mice (6-8 weeks old) | 100 mg/kg | 15 w | P13K/AKt, NF-κB | P13K, p-AKt, IKKα, IκBα, NF-κB, p65, p-p65, IL-1β, IL-6, TNF-α, Cyclin D1, survivin ↓ |
|
| Oroxylin A | HCT-116 | 25, 50, 100 μM | 1 h | Male and female | 50, 100, 200 mg/kg/d | 100 d | NF-κB, | IL-6, IL-1β, |
|
| Silibinin | IMCE and HCT-116 | 50, | 72 h | Female C57BL/6J mice (6 weeks old) | 750 mg/kg/d | 10 w | IL-6/STAT3 | IL-6, IL-1β, TNF-α, p-STAT3↓ |
|
| Nobiletin and its metabolites | RAW 264.7 cells, | 0.5, 1, 2 μg/ml | 24 h | Male CD-1 mice | 500 ppm nobiletin in diets | 20 w | Nrf2 pathway, | iNOS, cyclinE, cyclinD, CDK6, CDK4, CDK2 ↓ |
|
| Phytosomal curcumin | CT-26 | 0-1000 μM | 24/48/72 h | Female C57/6 mice (8 weeks old) | 25 mg/kg/d | 62 d | WNT | β-catenin,cyclin D1 ↓ |
|
| Resveratrol | Male and female C57BL/6 mice (8–12 weeks old) | 300 ppm resveratrol in diets | 9 w | Oxidative stress, NF-κB pathway | iNOS, COX-2, TNF-α, p53↓ |
| |||
| Isoliquiritigenin | Male BALB/c mice (6 weeks old) | 20,100,500 μg/ml isoliquiritige in diets | 12 w | Oxidative stress | iNOS, COX-2, CD206↓ |
| |||
| Pristimerin | Female BALB/c mice (5 weeks old) | 1-5 ppm Pristimerin diets | 10 w | NF-κ B, | P-AKT, p-FOXO3a, TNF-α, IL-6, |
| |||
| Celastrol | HCT116, | 0-40 μM | 24,48h | Male C57BL/6 mice (6-8 weeks old), | 2 mg/kg/d | 14 w | NF-κB pathway, | NF-κBp65, TNF-α, IL-6, IL-1β, COX-2, iNOS, p53, p-p53, N-cadherin, Vimentin, Snail, β-catenin ↓ |
|
| Triptolide | SW480 cells | 10, 30, 100, 300 nM | 24,48,72 h | Male ICR mice | 0.1, 0.3, 1 mg/kg/d | 20 w | JAK/STAT3 pathway, | IL-6R, IL-6, JAK1, |
|
| Crocin | Male ICR Mice (4 weeks old) | 50, 100, 200 ppm crocin in diets | 15/4 w | NF-κB signaling pathway | NF-κ B, COX-2, |
| |||
| Oleuropein | Female C57BL/6 mice | 50, 100 mg/kg | 8 w | NF-κB pathway, | p65, NF-κ B, TNF-α, β-catenin, Cox-2, IL-6, STAT3, AKt, IFN-γ, IL-17A↓ |
| |||
| Embelin | HCT116 | 20 μmol/L | 1-24 h | Male C57BL/6 mice (6-8weeks) | 50 mg/kg | 85 d | IL-6/STAT3 pathway | IL-6, p-STAT3, IL-1β, IL-17a, IL-23 ↓ |
|
| Parthenolide | Female Balb/C mice (6 weeks old) | 2, 4 mg/kg | 68 d | NF-κB pathway | IĸBα, NF-ĸB-p65, Bcl-2, Bcl-Xl ↓ |
| |||
| Extract of | HT-29 | 60, 120, 180 μg/ml | 6 h | Male ICR mice | 25 mg/kg/d | 9 w | NF-κB | P65, survivin, cFLIP, cIAP, XIAP, Bcl-2, Bcl-Xl, Mcl-1, TNF-α,P- IL-1β↓ |
|
| American Ginseng | ANA-1 murine macrophage, TK6 lymphoblastoid cells, | 260 μg/ml, 0-1000 μg/ml, | 24 h | Mice | 11.9 mg/kg/d | 35/50 d | Oxidative stress pathway | iNOS, COX-2 ↓ |
|
| Cocoa | Female BALB/c mice | 5%, 10% cocoa in diets | 62 d | NF-κB/ | Bcl-Xl, IL-6, CD68+, PCNA, IL-17, IL-1β, TNF-α, NF-κB, p-STAT3Y705↓ |
| |||
| Licorice flavoids (LFs) | Female C57BL/6 mice | 50, 100 mg/kg/d | 10 w | NF-κB/IL-6/Jak2/Stat3, p53 pathway | iNOS, Cox-2, IL-1β, IL-6, TNF-α, PCNA, NF-κB, IKKα/β,p-IκBp-Jak2, |
| |||
| Ganoderma lucidum triterpene extract | Male ICR mice (5weeks old) | 0, 100, 500 mg/kg (three times per week) | 17 w | NF-κB, cell cycle pathway | CyclinD1, COX-2, CYP1A2, |
| |||
| Nanoparticles derived from edible ginger | RAW264.7 cells, Caco-2BBE, Colon-26 cells | 0-100 μg/ml | 24h | Female C57BL/6 or FVB/NJ mice (6-8 weeks old) | 0.3 mg/mouse | 19 w | Cell cycle | TNF-α, IL-6, IL-1β, CyclinD1↓ |
|
| Tea polysaccharide | CT-26 cells | 20-320 μg/ml | 48h | BALB/c mice | 0-200 mg/kg | 13 w | Cell cycle pathway | CyclinD1, MMP-2, MMP-9↓ |
|
| Tea polyphenols | Male BALB/c mice (4 weeks old) | 0.1% in water | 42 days | WNT/β-catenin pathway | COX-2, TNF-α, IL-6, β-catenin, C-myc ↓ |
| |||
| Lentinan | RAW264.7 cells | 0.5, 1, 2 mg/ml | 24h | Female C57BL/6 mice, | 5, 10, 20 mg/kg, | 7 or 20 d, | TLR4/NF-κB | MyD88, IRAK4, TRAF6, IKBKB, NF-κB-p65, NF-κB, IL-13, CD30L ↓ |
|
| Huangqin Decoction | Male C57BL/6 mice (8-week old) | 9.1 g/kg | 16 w | Oxidative stress pathway | TNF-α, IL-1β, IL-6, CSF-1, MCP-1, COX-2, MPO, MDA,8-oxoguanine, nitrotyrosine ↓ |
| |||
| ShaoYao decoction (SYD) | Male C57BL/6J mice (6and 8 weeks old) | 7.12 g/kg, twice a day | 15 w | NF-κB pathway | β-catenin, COX-2, p53, p65, PCNA, N-cadherin, fibronectin, vimentin, Snail, IL-1β, IL-6, TNF-α↓ |
| |||
| Shenling Baizhu San | SW480, HCT116. Cells | 0-16 μg/ml | 12/24h | Male C57BL/6 J mice | 7.28 g/kg (twice a day) | 15 w | TGF-β1, | TGF-β1, Wnt5a, β-catenin, PCNA, p53, N-cadherin, vimentin, Fibronectin, Snail ↓ |
|